SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/13/18 Unitedhealth Group Inc 10-K 12/31/17 103:18M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.36M 2: EX-10.51 Material Contract HTML 68K 4: EX-21.1 Subsidiaries List HTML 229K 5: EX-23.1 Consent of Experts or Counsel HTML 30K 6: EX-24.1 Power of Attorney HTML 38K 3: EX-12.1 Statement re: Computation of Ratios HTML 42K 7: EX-31.1 Certification -- §302 - SOA'02 HTML 44K 8: EX-32.1 Certification -- §906 - SOA'02 HTML 33K 15: R1 Document and Entity Information Document HTML 58K 16: R2 Consolidated Balance Sheets HTML 125K 17: R3 Consolidated Balance Sheet (Parenthetical) HTML 55K 18: R4 Consolidated Statements of Operations HTML 97K 19: R5 Consolidated Statements of Comprehensive Income HTML 66K 20: R6 Consolidated Statements of Changes in Equity HTML 109K 21: R7 Consolidated Statements of Cash Flows HTML 124K 22: R8 Description of Business (Notes) HTML 30K 23: R9 Basis of Presentation, Uses of Estimates and HTML 95K Significant Accounting Policies (Notes) 24: R10 Investments (Notes) HTML 252K 25: R11 Fair Value (Notes) HTML 180K 26: R12 Property, Plant, and Capitalized Software (Notes) HTML 52K 27: R13 Goodwill and Intangible Assets (Notes) HTML 115K 28: R14 Medical Costs Payable (Notes) HTML 79K 29: R15 Commercial Paper and Long-Term Debt (Notes) HTML 237K 30: R16 Income Taxes (Notes) HTML 159K 31: R17 Shareholders' Equity (Notes) HTML 49K 32: R18 Share-Based Compensation (Notes) HTML 110K 33: R19 Commitments and Contingencies (Notes) HTML 48K 34: R20 Segment Financial Information (Notes) HTML 306K 35: R21 Quarterly Financial Data (Unaudited) (Notes) HTML 80K 36: R22 Schedule I (Notes) HTML 200K 37: R23 Basis of Presentation, Uses of Estimates and HTML 153K Significant Accounting Policies (Policies) 38: R24 Fair Value Fair Value (Policies) HTML 43K 39: R25 Schedule I (Policies) HTML 121K 40: R26 Basis of Presentation, Uses of Estimates and HTML 69K Significant Accounting Policies (Tables) 41: R27 Investments (Tables) HTML 250K 42: R28 Fair Value (Tables) HTML 170K 43: R29 Property, Plant, and Capitalized Software (Tables) HTML 50K 44: R30 Goodwill and Intangible Assets (Tables) HTML 120K 45: R31 Medical Costs Payable (Tables) HTML 80K 46: R32 Commercial Paper and Long-Term Debt (Tables) HTML 236K 47: R33 Income Taxes (Tables) HTML 160K 48: R34 Shareholders' Equity (Tables) HTML 41K 49: R35 Share-Based Compensation (Tables) HTML 113K 50: R36 Commitments and Contingencies (Tables) HTML 39K 51: R37 Segment Financial Information (Tables) HTML 297K 52: R38 Quarterly Financial Data (Unaudited) (Tables) HTML 80K 53: R39 Schedule I (Tables) HTML 204K 54: R40 Basis of Presentation, Uses of Estimates and HTML 86K Significant Accounting Policies (Details) 55: R41 Basis of Presentation, Uses of Estimates and HTML 41K Significant Accounting Policies Useful lives for property, equipment and capitalized software (Details) 56: R42 Basis of Presentation, Uses of Estimates and HTML 52K Significant Accounting Policies Redeemable Noncontrolling Interests (Details) 57: R43 Investments (Narrative) (Details) HTML 36K 58: R44 Investments (Short-Term and Long-Term Investments) HTML 95K (Details) 59: R45 Investments (Amortized Cost and Fair Value of HTML 103K Available-for-Sale Debt Securities by Contractual Maturity) (Details) 60: R46 Investments (Fair Value of Available-For-Sale HTML 73K Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) 61: R47 Investments (Net Realized Gains) (Details) HTML 48K 62: R48 Fair Value (Narrative) (Details) HTML 46K 63: R49 Fair Value (Financial Assets and Liabilities, HTML 88K Measured at Fair Value on a Recurring Basis) (Details) 64: R50 Fair Value (Financial Assets and Liabilities, Not HTML 78K Measured at Fair Value on a Recurring Basis) (Details) 65: R51 Property, Plant, and Capitalized Software HTML 34K (Details) 66: R52 Property, Plant, and Capitalized Software Property HTML 53K Plant and Equipment Table (Details) 67: R53 Goodwill and Intangible Assets (Details) HTML 32K 68: R54 Goodwill and Intangible Assets Changes in the HTML 49K Carrying Amount of Goodwill by Reporting Segment (Details) 69: R55 Goodwill and Intangible Assets Gross carrying HTML 47K value, accumulated amortization and net carrying value of intangible assets (Details) 70: R56 Goodwill and Intangible Assets Weighted-average HTML 41K useful lives assigned to finite-lived intangible assets acquired in business combinations (Details) 71: R57 Goodwill and Intangible Assets Amortization HTML 40K Expense relating to Intangible Assets (Details) 72: R58 Medical Costs Payable (Details) HTML 29K 73: R59 Medical Costs Payable Rollforward (Details) HTML 53K 74: R60 Medical Costs Payable, Incurred and Paid Medical HTML 43K Cost Development (Details) 75: R61 Commercial Paper and Long-Term Debt (Narrative) HTML 65K (Details) 76: R62 Commercial Paper and Long-Term Debt (Details) HTML 191K 77: R63 Commercial Paper and Long-Term Debt Maturities of HTML 45K commercial paper and long-term debt (Details) 78: R64 Income Taxes (Details) HTML 62K 79: R65 Income Taxes Reconciliation of Provision for HTML 46K Income Taxes (Details) 80: R66 Income Tax Reconciliation of the tax provision at HTML 80K the U.S. Federal Statutory Rate (Details) 81: R67 Income Taxes Components of Deferred Tax Assets and HTML 79K Liabilities (Details) 82: R68 Income Taxes Reconciliation of the beginning and HTML 45K ending amount of unrecognized tax benefits (Details) 83: R69 Shareholders' Equity (Details) HTML 45K 84: R70 Shareholders' Equity Share Repurchases (Details) HTML 40K 85: R71 Share-Based Compensation Narrative (Details) HTML 36K 86: R72 Share-Based Compensation (Stock Option and SAR HTML 76K Activity) (Details) 87: R73 Share-Based Compensation (Restricted Share HTML 46K Activity) (Details) 88: R74 Share-Based Compensation Other Share-Based HTML 61K Compensation Data (Details) 89: R75 Share-Based Compensation (Share-Based Compensation HTML 48K Principal Fair Value Assumptions) (Details) 90: R76 Commitments and Contingencies (Details) HTML 36K 91: R77 Commitments and Contingencies Future Lease HTML 45K Payments (Details) 92: R78 Segment Financial Information (Narrative) HTML 43K (Details) 93: R79 Segment Financial Information (Details) HTML 121K 94: R80 Quarterly Financial Data (Unaudited) (Details) HTML 61K 95: R81 Schedule I (Details) HTML 41K 96: R82 Schedule I Condensed Balance Sheets (Details) HTML 109K 97: R83 Schedule I Balance Sheet Document (Details) HTML 49K 98: R84 Schedule I Condensed Statement of Comprehensive HTML 66K Income (Details) 99: R85 Schedule I Statement of Cash Flows (Details) HTML 102K 100: R86 Schedule I Maturities of Commercial Paper and HTML 48K Long-Term Debt (Details) 102: XML IDEA XML File -- Filing Summary XML 190K 101: EXCEL IDEA Workbook of Financial Reports XLSX 133K 9: EX-101.INS XBRL Instance -- unh-20171231 XML 5.79M 11: EX-101.CAL XBRL Calculations -- unh-20171231_cal XML 313K 12: EX-101.DEF XBRL Definitions -- unh-20171231_def XML 1.44M 13: EX-101.LAB XBRL Labels -- unh-20171231_lab XML 2.38M 14: EX-101.PRE XBRL Presentations -- unh-20171231_pre XML 1.66M 10: EX-101.SCH XBRL Schema -- unh-20171231 XSD 219K 103: ZIP XBRL Zipped Folder -- 0000731766-18-000005-xbrl Zip 409K
Exhibit |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated
(the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change
in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Chief Executive Officer | |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ JOHN
F. REX | |
John F. Rex Executive Vice President and Chief Financial Officer |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/13/18 | 3, 4, 8-K, SC 13G/A | ||
For Period end: | 12/31/17 | 11-K | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/11/18 SEC UPLOAD¶ 5/09/18 1:38K UnitedHealth Group Inc. 3/22/18 SEC UPLOAD¶ 5/09/18 1:47K UnitedHealth Group Inc. |